In last trading session, Arbutus Biopharma Corp (NASDAQ:ABUS) saw 0.89 million shares changing hands with its beta currently measuring 0.86. Company’s recent per share price level of $3.13 trading at -$0.01 or -0.32% at ring of the bell on the day assigns it a market valuation of $599.48M. That closing price of ABUS’s stock is at a discount of -50.8% from its 52-week high price of $4.72 and is indicating a premium of 13.74% from its 52-week low price of $2.70. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.79 million shares which gives us an average trading volume of 814.77K if we extend that period to 3-months.
For Arbutus Biopharma Corp (ABUS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.50. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.09 in the current quarter.
Arbutus Biopharma Corp (NASDAQ:ABUS) trade information
Arbutus Biopharma Corp’s shares saw a change of -19.33% in year-to-date performance and have moved -1.26% in past 5-day. Arbutus Biopharma Corp (NASDAQ:ABUS) showed a performance of -9.28% in past 30-days. Number of shares sold short was 12.84 million shares which calculate 18.6 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 8.5 to the stock, which implies a rise of 63.18% to its current value. Analysts have been projecting 8.5 as a low price target for the stock while placing it at a high target of 8.5. It follows that stock’s current price would drop -171.57% in reaching the projected high whereas dropping to the targeted low would mean a loss of -171.57% for stock’s current value.
Arbutus Biopharma Corp (ABUS) estimates and forecasts
This year revenue growth is estimated to fall -11.10% from the last financial year’s standing.
4 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 2.21M for the same. And 4 analysts are in estimates of company making revenue of 2.18M in the next quarter. Company posted 2.39M and 1.86M of sales in current and next quarters respectively a year earlier. Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 33.46% during past 5 years.
Arbutus Biopharma Corp (NASDAQ:ABUS)’s Major holders
Insiders are in possession of 21.89% of company’s total shares while institution are holding 59.38 percent of that, with stock having share float percentage of 76.02%. Investors also watch the number of corporate investors in a company very closely, which is 59.38% institutions for Arbutus Biopharma Corp that are currently holding shares of the company. MORGAN STANLEY is the top institutional holder at ABUS for having 20.96 million shares of worth $64.77 million. And as of 2024-06-30, it was holding 11.1466 of the company’s outstanding shares.
The second largest institutional holder is WHITEFORT CAPITAL MANAGEMENT, LP, which was holding about 12.87 million shares on 2024-06-30. The number of shares represents firm’s hold over 6.8432 of outstanding shares, having a total worth of $39.76 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and Morgan Stanley Insight Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 4.87 shares of worth $15.25 million or 2.54% of the total outstanding shares. The later fund manager was in possession of 4.2 shares on Mar 31, 2025 , making its stake of worth around $13.14 million in the company or a holder of 2.19% of company’s stock.
